possible hypoglycemia.belladonna and opiumbelladonna and opium and thiothixene both increase sedation. Use Caution/Monitor.belladonna and opium decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna and opium decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.thiothixene increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benperidolbenperidol and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.benperidol and thiothixene both increase sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen and thiothixene both increase sedation. Use Caution/Monitor.benzphetaminethiothixene increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.benztropinethiothixene increases effects of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. .brexanolonebrexanolone, thiothixene. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and thiothixene both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and thiothixene both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and thiothixene both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and thiothixene both increase sedation. Use Caution/Monitor.buprenorphinebuprenorphine and thiothixene both increase sedation. Use Caution/Monitor.buprenorphine buccalbuprenorphine buccal and thiothixene both increase sedation. Use Caution/Monitor.buprenorphine subdermal implantbuprenorphine subdermal implant and thiothixene both increase sedation. Use Caution/Monitor.buprenorphine transdermalbuprenorphine transdermal and thiothixene both increase sedation. Use Caution/Monitor.buprenorphine, long-acting injectionthiothixene increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.buprenorphine, long-acting injection and thiothixene both increase sedation. Use Caution/Monitor.butabarbitalbutabarbital and thiothixene both increase sedation. Use Caution/Monitor.butalbitalbutalbital and thiothixene both increase sedation. Use Caution/Monitor.butorphanolbutorphanol and thiothixene both increase sedation. Use Caution/Monitor.caffeinethiothixene increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.cannabidiolcannabidiol, thiothixene. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition with the coadministration of CYP1A2 substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate.carbinoxaminecarbinoxamine and thiothixene both increase sedation. Use Caution/Monitor.carisoprodolcarisoprodol and thiothixene both increase sedation. Use Caution/Monitor.cenobamatecenobamate, thiothixene. Either increases effects of the other by sedation. Use Caution/Monitor.chloral hydratechloral hydrate and thiothixene both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and thiothixene both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and thiothixene both increase sedation. Use Caution/Monitor.chlorpromazinechlorpromazine and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and thiothixene both increase sedation. Use Caution/Monitor.chlorzoxazonechlorzoxazone and thiothixene both increase sedation. Use Caution/Monitor.cinnarizinecinnarizine and thiothixene both increase sedation. Use Caution/Monitor.cisatracuriumcisatracurium decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cisatracurium decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.thiothixene increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.citalopramthiothixene and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.clemastineclemastine and thiothixene both increase sedation. Use Caution/Monitor.clobazamthiothixene, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipraminethiothixene and clomipramine both increase sedation. Use Caution/Monitor.clonazepamclonazepam and thiothixene both increase sedation. Use Caution/Monitor.clonidineclonidine, thiothixene. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.clorazepateclorazepate and thiothixene both increase sedation. Use Caution/Monitor.clozapineclozapine and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.clozapine and thiothixene both increase sedation. Use Caution/Monitor.codeinecodeine and thiothixene both increase sedation. Use Caution/Monitor.crizotinibcrizotinib and thiothixene both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.cyclizinecyclizine and thiothixene both increase sedation. Use Caution/Monitor.cyclizine decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cyclizine decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.thiothixene increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyclobenzaprinecyclobenzaprine and thiothixene both increase sedation. Use Caution/Monitor.cyclobenzaprine decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cyclobenzaprine decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.thiothixene increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyproheptadinecyproheptadine and thiothixene both increase sedation. Use Caution/Monitor.dantrolenedantrolene and thiothixene both increase sedation. Use Caution/Monitor.daridorexantthiothixene and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacindarifenacin decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.darifenacin decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.thiothixene increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.desfluranedesflurane and thiothixene both increase sedation. Use Caution/Monitor.desipraminethiothixene and desipramine both increase sedation. Use Caution/Monitor.desipramine and thiothixene both increase QTc interval. Use Caution/Monitor.deutetrabenazinethiothixene and deutetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely. The risk for parkinsonism, neuroleptic malignant syndrome, and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics.thiothixene and deutetrabenazine both increase sedation. Use Caution/Monitor.deutetrabenazine and thiothixene both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexchlorpheniraminedexchlorpheniramine and thiothixene both increase sedation. Use Caution/Monitor.dexfenfluraminethiothixene increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexmedetomidinedexmedetomidine and thiothixene both increase sedation. Use Caution/Monitor.dexmethylphenidatethiothixene increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetaminethiothixene increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextromethorphandextromethorphan, thiothixene. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).dextromoramidedextromoramide and thiothixene both increase sedation. Use Caution/Monitor.diamorphinediamorphine and thiothixene both increase sedation. Use Caution/Monitor.diazepamdiazepam and thiothixene both increase sedation. Use Caution/Monitor.dicyclominedicyclomine decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.dicyclomine decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.thiothixene increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.diethylpropionthiothixene increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.difelikefalindifelikefalin and thiothixene both increase sedation. Use Caution/Monitor.difenoxin hcldifenoxin hcl and thiothixene both increase sedation. Use Caution/Monitor.dihydroergotaminedihydroergotamine, thiothixene. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).dimenhydrinatedimenhydrinate and thiothixene both increase sedation. Use Caution/Monitor.diphenhydraminediphenhydramine and thiothixene both increase sedation. Use Caution/Monitor.diphenhydramine decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.diphenhydramine decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.thiothixene increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.diphenoxylate hcldiphenoxylate hcl and thiothixene both increase sedation. Use Caution/Monitor.dipipanonedipipanone and thiothixene both increase sedation. Use Caution/Monitor.dobutaminethiothixene increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.donepezil transdermaldonepezil transdermal, thiothixene. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dopaminethiothixene increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopexaminethiothixene increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepinthiothixene and dosulepin both increase sedation. Use Caution/Monitor.doxepinthiothixene and doxepin both increase sedation. Use Caution/Monitor.doxepin and thiothixene both increase QTc interval. Use Caution/Monitor.doxylaminedoxylamine and thiothixene both increase sedation. Use Caution/Monitor.droperidoldroperidol and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.droperidol and thiothixene both increase sedation. Use Caution/Monitor.eletriptaneletriptan, thiothixene. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).eliglustateliglustat and thiothixene both increase QTc interval. Use Caution/Monitor.ephedrinethiothixene increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.epinephrinethiothixene increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.epinephrine racemicthiothixene increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ergoloid mesylatesergoloid mesylates, thiothixene. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).ergotamineergotamine, thiothixene. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).esketamine intranasalesketamine intranasal, thiothixene. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.estazolamestazolam and thiothixene both increase sedation. Use Caution/Monitor.ethanolthiothixene and ethanol both increase sedation. Use Caution/Monitor.ezogabineezogabine, thiothixene. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.fenfluraminethiothixene increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.fentanylfentanyl, thiothixene. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).fesoterodinefesoterodine decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.fesoterodine decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.thiothixene increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.fexinidazolefexinidazole will increase the level or effect of thiothixene by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.flavoxateflavoxate decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.flavoxate decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.thiothixene increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.flibanserinflibanserin, thiothixene. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).fluoxetinethiothixene and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.fluphenazinefluphenazine and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.fluphenazine and thiothixene both increase sedation. Use Caution/Monitor.flurazepamflurazepam and thiothixene both increase sedation. Use Caution/Monitor.formoterolthiothixene increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.frovatriptanfrovatriptan, thiothixene. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).ganaxolonethiothixene and ganaxolone both increase